BCL2 and hematologic disorder: The Bcl-2 inhibitor venetoclax (VEN) is capable of targeting the anti-apoptotic protein Bcl-2, inducing apoptosis in tumor cells without relying on genetic mutations, and has shown great advantages in the treatment of hematologic malignancies (3–5).